Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Leases (2016 - 2018)

Historic Capital Leases for Amphastar Pharmaceuticals (AMPH) over the last 6 years, with Q4 2018 value amounting to $1.1 million.

  • Amphastar Pharmaceuticals' Capital Leases fell 2225.5% to $1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.1 million, marking a year-over-year decrease of 2225.5%. This contributed to the annual value of $1.1 million for FY2018, which is 2225.5% down from last year.
  • According to the latest figures from Q4 2018, Amphastar Pharmaceuticals' Capital Leases is $1.1 million, which was down 2225.5% from $1.1 million recorded in Q3 2018.
  • In the past 5 years, Amphastar Pharmaceuticals' Capital Leases registered a high of $1.9 million during Q2 2016, and its lowest value of $802000.0 during Q4 2015.
  • Moreover, its 5-year median value for Capital Leases was $1.2 million (2018), whereas its average is $1.3 million.
  • Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 10124.69% in 2016, then tumbled by 2225.5% in 2018.
  • Over the past 5 years, Amphastar Pharmaceuticals' Capital Leases (Quarter) stood at $1.0 million in 2014, then fell by 21.53% to $802000.0 in 2015, then skyrocketed by 101.25% to $1.6 million in 2016, then fell by 15.92% to $1.4 million in 2017, then fell by 22.25% to $1.1 million in 2018.
  • Its last three reported values are $1.1 million in Q4 2018, $1.1 million for Q3 2018, and $1.2 million during Q2 2018.